Correction of Exon 2, Exon 2-9 and Exons 8-9 duplications in DMD patient myogenic cells by a Single CRISPR/Cas9 system
RNA-seq (gene expression) · human · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 21 samples: 21 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 systemScientific reports · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE272233_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1135907 and SRA study SRP519884. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 21 sample titles: 21 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8396124 ips, WT [C25-1]
- GSM8396125 ips, DupExon2, untreated [dup2-1]
- GSM8396126 ips, DupExon2, edited, [dup2cl7-1]
- GSM8396127 ips, DupExon2-9, untreated [dup2-9]
- GSM8396128 ips, DupExon2-9, edited [dup2-9cl14-1]
- GSM8396129 ips, DupExon8-9, untreated [dup8-9-1]
- GSM8396130 ips, DupExon8-9, edited [dup8-9cl12-1]
- GSM8396131 ips, WT [C25-2]
- GSM8396132 ips, DupExon2, untreated [dup2-2]
- GSM8396133 ips, DupExon2, edited, [dup2cl7-2]
- GSM8396134 ips, DupExon2-9, untreated [dup2-9-2]
- GSM8396135 ips, DupExon2-9, edited [dup2-9cl14-2]
- GSM8396136 ips, DupExon8-9, untreated [dup8-9-2]
- GSM8396137 ips, DupExon8-9, edited [dup8-9cl12-2]
- GSM8396138 ips, WT [C25-3]
- GSM8396139 ips, DupExon2, untreated [dup2-3]
- GSM8396140 ips, DupExon2, edited, [dup2cl7-3]
- GSM8396141 ips, DupExon2-9, untreated [dup2-9-3]
- GSM8396142 ips, DupExon2-9, edited [dup2-9cl14-3]
- GSM8396143 ips, DupExon8-9, untreated [dup8-9-3]
- GSM8396144 ips, DupExon8-9, edited [dup8-9cl12-3]
- GSE290621 Quadruple adenine base edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease engineered T cells [RNA-seq] 33 samples shares crispr, cas9
- GSE301632 Genome-wide CRISPR-Cas9 knockout screening identifies NUDCD2 depletion as sensitizer for bortezomib, carfilzomib and ixazomib in multiple myeloma. 27 samples shares crispr, cas9
- GSE303100 Dissecting Resistance to CDK4/6 Inhibition in Experimental Glioma via Genome-wide CRISPR-Cas9 Screening 24 samples shares crispr, cas9
- GSE248671 Gene expression analysis of human sickle cell disease (SCD) and healthy donor (HD) CD34+ hematopoietic stem/progenitor cells (HSPCs) treated with CRISPR/Cas9 targeting the HBG promoters or untreated samples 24 samples shares crispr, cas9
- GSE240468 Silencing of NFYC-AS1 by Gapmer antisense oligonucleotides and CRISPR/Cas9 TSS deletion. 23 samples shares crispr, cas9
- GSE283554 A CRISPR/Cas9-based enhancement of high-throughput single-cell transcriptomics 22 samples shares crispr, cas9
- GSE226978 RNA-Sequencing Analysis of LNCaP Wildtype (WT) and RB-p53 CRISPR-Cas9 Double Knockout (DKO) Cells Treated with Enzalutamide 16 samples shares crispr, cas9
- GSE319117 Simultaneous orthogonal cell engineering by a single CRISPR-Cas9 polyfunctional editor [RNA-seq T-cells B2M/TET2/TGFBR2] 14 samples shares crispr, cas9
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.